|Bid||218.00 x 2200|
|Ask||218.95 x 1100|
|Day's range||218.32 - 221.05|
|52-week range||129.21 - 235.85|
|Beta (5Y monthly)||0.24|
|PE ratio (TTM)||32.72|
|Earnings date||03 Aug 2021|
|Forward dividend & yield||3.40 (1.56%)|
|Ex-dividend date||13 May 2021|
|1y target est||216.36|
In May, the Biden administration backed the idea of waiving intellectual property protections for COVID-19 vaccines. In a new interview, pharmaceutical giant Eli Lilly CEO David Ricks weighed in says “this is a counterproductive move.”
AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.
In the latest trading session, Eli Lilly (LLY) closed at $222.21, marking a +0.66% move from the previous day.